PE-Labeled CEACAM-5/CD66e Fc&Avi Tag: A "Modular Multifunctional Navigator" for Epithelial Cancer Diagnosis and Treatment

PE-Labeled CEACAM-5/CD66e Fc&Avi Tag is an advanced recombinant protein probe designed for a key member of the carcinoembryonic antigen family. Carcinoembryonic antigen-related cell adhesion molecule 5 is a member of the immunoglobulin superfamily, expressed in trace amounts in normal adult colonic mucosa and other epithelial tissues, but shows specific high expression in various epithelial-derived malignancies such as colorectal cancer, non-small cell lung cancer, gastric cancer, breast cancer, and pancreatic cancer. It is one of the most widely used serum tumor markers and a highly promising therapeutic target. This probe integrates multiple modules including the CEACAM-5 extracellular targeting domain, universal Fc interface, programmable AviTag, and ultra-bright PE fluorescent reporting system, creating a comprehensive platform with ultra-high sensitivity detection, functional manipulation, and unlimited derivative expansion capabilities. It aims to provide core technical support for the precise diagnosis, prognosis assessment, and targeted therapy development of epithelial cancers.

This protein is an "all-in-one" tool platform constructed based on modular engineering principles, designed to maximize the research and clinical application value of CEACAM-5 as a pan-cancer marker.

The core of the probe is the extracellular immunoglobulin-like domain of human CEACAM-5 protein. CEACAM-5 is a glycosylated cell surface adhesion molecule whose extracellular domain mediates homotypic and heterotypic interactions, participating in cell recognition, aggregation, and signal transduction. This module retains the ability to specifically bind to naturally occurring CEACAM-5 antigens on cell surfaces and can recognize soluble forms of CEACAM-5 in serum.

The fused human IgG Fc fragment serves as a "multifunctional adapter" in this platform:

Universal Signal Conversion and Cascade Amplification: Provides a universal binding site for anti-Fc secondary antibodies of any species and labeling form, allowing users to flexibly "map" detection signals to different fluorescence channels or employ multi-level amplification strategies to address the challenges of detecting extremely low-abundance targets.

Simulating Antibody Function and Inducing Endocytosis: Through anti-Fc antibodies, the probe can achieve cross-linking on the cell surface, mimicking the binding and clustering effects of therapeutic antibodies, used to study antibody-induced receptor endocytosis, signal regulation, or as a model for evaluating the endocytosis efficiency of ADC drugs.

A short peptide tag that can be efficiently biotinylated by biotin ligase, serving as the platform's "programmable expansion dock":

On-Demand Functional Customization: After biotinylation, it can be rapidly and highly affinitively coupled with any streptavidin-conjugated functional module (including different fluorescent dyes, magnetic beads, enzymes, radionuclides, or toxin molecules) via streptavidin bridging, achieving flexible configuration of "one core, infinite applications."

The probe is pre-covalently labeled with R-phycoerythrin, providing powerful initial detection capability:

Ensuring Overwhelming Signal-to-Noise Ratio for Basic Detection: PE's extremely high fluorescence intensity provides unparalleled high sensitivity and specificity when performing rapid screening of complex clinical samples (such as blood, pleural effusion, ascites) or identifying rare cells (such as circulating tumor cells).

This probe is a "four-in-one" strategic platform. The CEACAM-5 domain is the "guidance head" that precisely locks onto tumor-associated antigens; PE is the "main combat unit" that performs direct, powerful optical reconnaissance; the Fc tag is the "standardized data link" that coordinates various external support and tactical synergies; and the AviTag is the "frontier technology interface" that can access cutting-edge specialized equipment (diagnostic and therapeutic integrated modules). The synergy of the four achieves full-chain coverage of CEACAM-5 target research from "discovery" and "analysis" to "intervention."

This platform supports multiple "operation modes" from basic screening to cutting-edge mechanism exploration, adapting to different scenario requirements.

PE Ultra-Bright One-Step Labeling: Without the need for secondary antibodies, it achieves extremely high-brightness fluorescence labeling of CEACAM-5-positive cells or CTCs. PE's powerful signal can effectively overcome background interference in clinical samples, making it particularly suitable for rapid intraoperative pathological assessment or rapid preliminary screening of liquid biopsy samples.

Resolving Multi-Color Panel Conflicts: When constructing ultra-high-parameter flow cytometry or imaging panels, if the PE channel is already occupied, the Fc tag can be used to select anti-Fc secondary antibodies conjugated with APC, BV785, and other dyes for detection, "translating" the CEACAM-5 signal to other idle channels to achieve ultra-multiparameter lossless analysis.

Cascade Amplification of Weak Signals: For samples with antigen downregulation after treatment or extremely low baseline expression, a multi-step method of "probe + biotinylated anti-Fc secondary antibody + streptavidin-fluorescent polymer" can be used to achieve exponential amplification of signals, reaching single-molecule detection-level sensitivity.

Simulating the Mechanism of Therapeutic Antibodies: Using Fc tag-mediated cross-linking, it can induce CEACAM-5 receptor aggregation and internalization, used to study antibody-dependent cell-mediated cytotoxicity, antibody-dependent cell-mediated phagocytosis, and the endocytosis kinetics of ADC drugs.

Competitive Blocking and Validation: As a high-affinity soluble receptor, it can be used to competitively block the binding of endogenous ligands or therapeutic antibodies (such as Labetuzumab) to target cells, validating the target specificity of related functions or efficacy.

Rapid Construction of Specialized Tools: Through AviTag biotinylation, the platform core can be converted within hours into a near-infrared probe for small animal in vivo imaging, a magnetic bead conjugate for cell sorting, or a specialized marker for three-dimensional imaging after tissue clearing, greatly improving R&D efficiency.

This platform plays a pivotal role in the research, diagnosis, monitoring, and therapeutic development of various epithelial malignancies.

Specific "Probe" for Circulating Tumor Cell Detection: Utilizing PE's ultra-high brightness, it can sensitively and specifically enrich and identify CEACAM-5-positive CTCs from the peripheral blood of patients with colorectal cancer, lung cancer, and other malignancies. CTC counting and typing are important liquid biopsy indicators for assessing tumor metastasis risk, prognosis, and efficacy.

Differential Diagnosis of Malignant Effusions: In pleural effusion and ascites samples, it can quickly distinguish CEACAM-5-positive adenocarcinoma cells from reactive mesothelial cells, assisting in tumor staging and metastasis diagnosis.

Innovative Platform for Serum Marker Detection: Based on Fc or AviTag immobilization of the probe, it can develop ultra-sensitive homogeneous or heterogeneous immunoassays to accurately quantify the level of soluble CEACAM-5 in serum, used for auxiliary diagnosis, efficacy monitoring, and recurrence warning.

Tumor Tissue-Specific Labeling and Differential Diagnosis: In tissue section multiplex immunofluorescence staining, it serves as a key marker to specifically identify cancerous tissue and differentiate adenocarcinoma (usually CEACAM-5+) from other types of tumors (such as squamous cell carcinoma, sarcoma).

Spatial Analysis of the Tumor Microenvironment: Combined with other markers, it can perform in situ analysis of the spatial relationship between CEACAM-5+ tumor cells and CD8+ T cells, Tregs, tumor-associated macrophages, etc., revealing the cellular basis of immune exclusion or inflammatory microenvironments.

Metastasis Origin Tracing: In metastatic cancer tissues of unknown primary origin, CEACAM-5 positivity strongly suggests that the primary site may be gastrointestinal or lung adenocarcinoma, assisting in clinical diagnosis.

Target Expression Profile Assessment: Precisely quantifies the antigen density, distribution uniformity, and endocytic activity of CEACAM-5 on the surface of different tumor models, providing key parameters for ADC drug design.

Drug Endocytosis and Pharmacodynamic Studies: By simulating antibody binding and endocytosis or acting as a competitor, it evaluates the targeting efficiency and endocytosis kinetics of ADC drugs.

Patient Screening and Stratification: Standardized detection of CEACAM-5 expression levels in patient tumors is a necessary step for entering related CAR-T clinical trials.

Efficacy Dynamics and Escape Monitoring: Dynamically monitors changes in CEACAM-5 antigen expression in CTCs or biopsy tissues after treatment, assesses the clearance pressure of CAR-T cells, and warns of antigen-negative escape.

Bispecific Antibody and Radioimmunotherapy Evaluation: As a standardized target antigen, it is used to evaluate and optimize the binding properties and functions of novel bispecific antibodies or radioimmunoconjugates.

Studying the Biological Functions of CEACAM-5: Investigates its role as an adhesion molecule in tumor cell aggregation, detachment, invasion, and colonization, as well as its impact on intracellular signaling pathways.

Exploring Its Role as an Immune Regulatory Molecule: Recent studies have found that CEACAM-5 can interact with molecules such as CEACAM-1 on T cells, potentially transmitting inhibitory signals. This probe can be used to study its new functions in tumor immune escape.

As a platform tool, its future development will deeply integrate with the frontiers of precision medicine.

Single-Cell Multi-Omics CTC Analysis: Using this platform to sort individual CEACAM-5+ CTCs for genomic, transcriptomic, and methylomic sequencing enables non-invasive panoramic monitoring of tumor molecular evolution and clonal dynamics.

Exosome Surface Protein Profiling: Through AviTag-derived probes, it captures CEACAM-5-positive tumor-derived exosomes in blood, analyzing their proteome and RNA cargo to develop novel liquid biopsy markers.

Using AviTag to conjugate the probe with NIR-II fluorescent dyes or radionuclides, it develops versions for intraoperative fluorescence/radioactive navigation. During tumor resection, it displays tumor boundaries and micrometastases in real time, guiding submillimeter-level precision resection.

Based on this platform, it develops standardized, automated flow cytometry or digital pathology detection solutions for clinical laboratories, serving as companion diagnostic tools for CEACAM-5-targeted drugs (such as ADCs, CAR-T, bispecific antibodies) to guide precise patient stratification.

Using high-quality, highly specific tissue staining images generated by this probe, it trains AI models to automatically identify and quantify CEACAM-5 expression patterns and spatial heterogeneity, combining clinical data to construct prognostic prediction models and efficacy response models.

Develops intelligent probes integrating diagnosis and treatment: the same AviTag-conjugated core module can be separately conjugated with diagnostic fluorescent dyes and therapeutic radionuclides/toxins. Achieving "see first, treat later," i.e., preoperative/intraoperative imaging localization and postoperative/intraoperative targeted treatment, completing the diagnostic and therapeutic loop.

PE-Labeled CEACAM-5 Fc&Avi Tag is a highly integrated "modular multifunctional navigator" in the field of tumor research and translational medicine. Centered on CEACAM-5, a classic pan-epithelial cancer marker, it integrates the strongest optical signal, the most versatile functional interface, and the most flexible programmability through engineering ingenuity, constructing a powerful platform applicable to the entire chain from basic research to clinical diagnosis and treatment. From serving as a sensitive "capture net" for CTCs in liquid biopsy to becoming a precise "identification code" for tumor cells in histopathology; from empowering the rational design of next-generation ADC drugs to safeguarding the clinical translation of innovative CAR-T therapies, this "four-in-one" platform is becoming one of the core engines driving the development of precision medicine for epithelial cancers. In the future, with further integration of liquid biopsy, molecular imaging, artificial intelligence, and cell therapy, this programmable, intelligent molecular platform will continue to evolve, not only as a research and diagnostic tool but also as a strategic bridge connecting target discovery, drug development, and clinical implementation, contributing indispensable strength to the ultimate realization of personalized, precision treatment for solid tumors.